Animal study · mice
Pemvidutide cut body weight about 25% in mice with NASH
Checked against the paper Animal studyPublished by PepVault
The takeaway
In a mouse model of NASH, pemvidutide beat semaglutide and elafibranor on weight and several liver measures, but this is early animal evidence, not a human result.
- Kind
- Animal study
- Studied in
- Mice
- Published
- 2022
- Journal
- Sci Rep
What they tested
The team tested how pemvidutide (ALT-801) compared with semaglutide and elafibranor on weight and liver disease in a mouse model of NASH, a fatty liver disease with inflammation.
How the study was done
A study in male C57BL/6J mice fed a NASH-inducing diet for 32 weeks, with liver fat and scarring confirmed by biopsy, a small tissue sample. They then got pemvidutide, semaglutide, elafibranor or vehicle (an inactive control) daily for 12 weeks while staying on the diet.

Model. Individual results vary.
What they found
In mice, pemvidutide reduced body weight by about 25%. It also lowered blood liver enzymes and blood total cholesterol, cut fat and cholesterol in the liver, and improved liver steatosis (fat buildup), with bigger drops than semaglutide or elafibranor (p < 0.05). It lowered galectin-3, an inflammation marker, and collagen type 1 alpha 1, a scarring marker, compared with vehicle (p < 0.05), and cut galectin-3 more than elafibranor (p < 0.05). Every mouse on pemvidutide improved its NAS, a combined score of fatty liver disease activity, compared with the active controls.
What it doesn’t show
This was a mouse study, so it doesn't show the same effects in people. It used only male mice and lasted 12 weeks of treatment.
The paper
Nestor et al. Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis. Sci Rep. 2022.
The compound
More studies on Pemvidutide
- Pemvidutide: liver fat down 54.7% at 48 weeks in IMPACT MASH trialRandomized trial · people · 2026
- Pemvidutide: up to 76.4% liver fat reduction at 24 weeks in MASLDRandomized trial · people · 2025
- Pemvidutide: MASH resolved in up to 58% vs 20% on placebo at 24 weeksRandomized trial · people · 2025
- Every study on Pemvidutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.